Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

Among women aged 27–45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was also generally well tolerated and highly immunogenic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Maldonado, Ivette, Plata, Manuel, Gonzalez, Mauricio, Correa, Alfonso, Nossa, Claudia, Giuliano, Anna R., Joura, Elmar A., Ferenczy, Alex, Ronnett, Brigitte M., Stoler, Mark H., Jin Zhou, Hao, Joshi, Amita, Das, Rituparna, Bautista, Oliver, Group, Thomas, Luxembourg, Alain, Saah, Alfred, Buchwald, Ulrike Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
HPV – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481115/
https://www.ncbi.nlm.nih.gov/pubmed/35853188
http://dx.doi.org/10.1080/21645515.2022.2078626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481115/
https://www.ncbi.nlm.nih.gov/pubmed/35853188
http://dx.doi.org/10.1080/21645515.2022.2078626

Ejemplares similares